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In biological fluids IGF-I and IGF-II are bound to specific, high-afRnity binding protein (BPS). Two human BPS have 
been isolated, one from serum, which is GHdependent, the other from amniotic fluid (AF BP), and their cDNAs have 
recently been cloned. We report here the isolation of another, new species from cerebrospinal f uid (CSF) where this 
BP predominates. The protein was purifted to homogeneity by a four-step procedure: gel filtration, chromatofocusing, 
hy~ophobic-infraction chromato~aphy and reverse-phase c~o~to~phy. Thereafter, SDS-polyacrylamide gel eleo 
trophoresis gave an M, of 34 000 (non-reduced), chromatofocusing gave an isoelectric point of 5.0, and its affinity for 
IGF-II (3 x 10”’ M1) was 10 times that for IGF-I. The N-terminal amino acid sequence of the first 15 residues determined 
in a BP preparation from the CSF of children was Leu-Ala-Pro-Gly-(~-Gly-Gln-Gly-Val-Gln-Ala-Gly-Ala-Pro-Gly. A
similar sequence was found for adult CSF, apart from residues 12 and 13 f-Leu-Leu-). These are highly analogous with 
the sequences starting from residue 69 of the GH-dependent BP, and from residue 61 of the AF BP. The new BP isolated 
is therefore related to, but distinct from, the other human BPS. 
Insulin-like growth factor; IGF-binding protein; Protein puritication; Amino acid sequence; Cerebrospinal Buid 
1. INTRODUCTION 
Over the past few years we have identified 
several forms of IGF-binding protein (BP) with 
different physico-chemical properties, regulation 
and affinities for IGF-I and IGF-II [l-4]. In man, 
five forms with it4, values of 41500,38 500,34000, 
30000 and 24000 are identifiable by ligand blot- 
ting. All these forms are present in all biological 
fluids, but the relative proportions vary with tissue 
of origin [2,3,5]. The 41.5 and 38.5 kDa BPS, 
whose synthesis appears to be under the control of 
growth hormone (GH) [3,4], represent wo forms 
of the same protein which has been purified from 
serum and the cDNA of which has recently been 
cloned [6,7]. The circulating forms of the 34 and 
30 kDa BPS appear to be negatively controlled by 
GH [3,4]. The BP corresponding to the 30 kDa 
form has been purified from amniotic fluid [8,9], 
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the placenta [lo] and Hep G2 human hepatoma 
culture medium [11,12]. In addition, several 
groups have cloned its cDNA [ 13-161. We noted [4] 
that in immunoblotting experiments the 34 kDa BP 
was immunologically unrelated both to the 41.5 
and 38.5 kDa BPS which are recognized by the 
anti-GH-dependent BP antibody [17] and to the 
30 kDa BP which is recognized by the anti- 
amniotic fluid BP antibody [lg]. 
We had previously reported that the 34 kDa BP 
was predominant in cerebrospinal fluid (CSF) and 
that is was probably responsible for the selective af- 
finity for IGF-II of the BPS extracted from this 
fluid [2,19]. We therefore undertook to isolate and 
purify the BP from CSF. 
2. MATERIALS AND METHODS 
2.1. Biological samples and peptides 
CSF samples collected uring neuroradiological examination 
of adults aud during treatment of hy~ocephaly in children gave 
us two 700 ml pools. Pure IGF-I (prep. I/4) and IGF-II (prep. 
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1115) were generously provided by Dr R.E. Humbel (Zurich, 
Switzerland). IGF-II was iodinated using the chloramine T 
method, with subsequent purification by gel filtration. 
2.2. Ulirafiltration 
Membranes with a cut-off of 10000 were used (Centiprep, 
Amicon, USA). 
2.3. Gel filtration 
A 1.5 x 90 cm column of Ultrogel AcA54 (IBF, France) 
equilibrated with 0.025 M bis-Tris-HCl, 0.1 M ammonium sul- 
phate, pH 7.4, was used. Chromatography was performed at 
4°C at a flow rate of 15 ml/h (1 ml/fraction). 
2.4. Chromatofocusing 
A Mono P anion-exchanger column (HR 10/20, FPLC 
system, Pharmacia, Sweden) equilibrated with 0.025 M 
bis-Tris-HCl, pH 6.5, was used. The proteins were eluted in a 
gradient of pH 6.5-4.0 with polybuffer 74HCl, pH 4.0, (lo%, 
v/v) at a flow rate of 0.5 ml/min and collected at 4°C in 1 ml 
fractions. 
2.5. Hydrophobic-interaction chromatography 
A phenyl-Superose column (HR 10110, FPLC system) 
equilibrated with 0.025 M bis-Tris-HCl, 1 M ammonium sul- 
phate, pH 6.5, was used. The proteins were eluted within 45 min 
in a descending ionic strength gradient, from 1 to 0 M 
(NH&SO4, at a flow rate of 1 mb’min and collected at 4°C in 
1 ml fractions. 
2.6. Reverse-phase chromatography 
A 4.6 x 250 mm column of C8 Aquapore RP 300 (Brownlee 
Labs, USA) with an HPLC system (Gilson, France) was used. 
The column was equilibrated with an aqueous olution of 0.1 Qo 
(v/v) trifluoroacetic acid (TFA). The proteins were eluted within 
30 min in a linear gradient from 0 to 100% isopropanol, 0.1 Qo 
TFA at a flow rate of 1 ml/min and collected at 4°C in 0.5 ml 
fractions. 
2.7. Characterization and assays 
The proteins were assayed according to Bradford [20]. 
2.7.1. SDS-polyacrylamide gel electrophoresis and ligand 
blotting 
Electrophoresis was performed on I1 Qo acrylamide slab gels 
(15 x 15 x 0.1 cm) according to Laemmh [21]. Gels were stain- 
ed either with Coomassie blue or silver 1221. 
Ligand blotting was performed as previously described 1231. 
After SDS-PAGE (without reducing agent, except in the case of 
the markers), the proteins were electroblotted onto a nitro- 
cellulose sheet and the BPS identified using ‘251-Iabelled IGF-II 
as probe. 
Binding activity assay was performed as described [24]. The 
samples were gel filtered in 1 M CHKOOH, 0.15 M NaCl, 
0.1% BSA in order to separate the BPS from the IGFs. The 
relative BP concentration was assessed by comparing the bind- 
ing to ‘Z51-labelled IGF-II with that of a reference CSF BP 
preparation arbitrarily assigned a value of 1 U BP/ml. Sampies 
were studied at 6 concentrations, each in duplicate. Incubation 
time was 24 h. Charcoal was used for the separation step. 
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2.7.2. Competitive-binding experiment [19] 
This was performed using an aliquot of the purified CSF BP 
preparation. Before assaying it was submitted to acidic gel 
filtration in order to separate the BPS from residual endogenous 
IGFs. The amount of BP binding approximately 25% *?- 
labelled IGF-II was determined and thereafter displacement 
curves were established using increasing concentrations of IGF-I 
and IGF-II, each in duplicate. 
2.7.3. N-terminal amino acid sequence 
All sequence data were obtained using either an Applied Bio- 
systems 470 A or 477 A protein sequencer with an on-line 120 A 
PTH analyser . 
3. RESULTS 
3.1. Purification scheme 
3.1.1. Step 1 
/ 
Samples of CSF (100 ml initial volume) were 
concentrated to 3 ml by ultrafiltration and in- 
cubated overnight at 4°C with ‘2’I-labelled IGF-II, 
then gel filtered at pH 7.4 (fig.1). The ‘251-IGF- 
II-BP complexes eluted in a peak with a & of 0.40 
corresponding to material with an apparent M, of 
40000. The elution profile of the radioactivity and 
that of the 34 kDa BP analysed by ligand blotting 
were superimposed. This BP appeared as a single 
band in adults and as a doublet in children. The 
fractions corresponding to the summit of the peak 
were pooled, concentrated by ultrafiltration and 
rechromatographed under the same conditions to 
eliminate the maximum amount of albumin and 
41.5 and 38.5 kDa BPS. The eluate of the second 
gel filtration was desalted and concentrated by 
ultrafiltration in 0.025 M bis-Tris-HCl, pH 6.5. 
3.1.2. Step 2 
The material obtained from the seven gel filtra- 
tions (corresponding to the 700 ml initial CSF) was 
applied to the Mono P anion exchanger and then 
chromatofocused as described above (fig.2). The 
1251-IGF-II-BP complexes eluted in a single peak 
around pH 5. Binding activity measurements of ali- 
quots precipitated with 85% ammonium sulphate 
and submitted to acidic gel filtration showed max- 
imum binding activity to correspond to the radio- 
activity peak. 
3.1.3. Step 3 
The chromatofocusing eluate was brought to 
high ionic strength (1 M ammonium sulphate in 
bis-Tris, pH 6.5) in preparation for hydrophobic- 
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Fig.1. Gel fiItration on Ultrogel AcAS4 at PI-I 7.4 of the CSF 
concentrated by ultrafiltration. The material (100 ml equivalent 
of CSP) bad previously been incubated with ‘2sI-labelled IGF- 
II. The radioactivity profile corresponds to the elution zone of 
the IGF-BP complex. An aliquot of each fraction was analysed 
by SDS-PAGE and ligand blotting. 
interaction chromatography. After being kept 
overnight at 4”C, the sample was cent~fuged 
(50000 x g for 30 min) and the supernatant 
chromatographed on the phenyl-Superose column 
as described above. 
3.1.4. Step 4 
TFA (0.1% final) was added to the eluate from 
step 3 which was then subjected to reverse-phase 
chromatography as described above (fig.3). The 
absorbance profile at 254 nm revealed a homo- 
geneous peak at 60% isopropanol. This material 
was rechromatographed, yielding a single peak in 
the same position. IGF-II eluted at 55% iso- 
propanol. 
3.2. Protein content and BP recovery 
The total protein content (average of the two 
purifications) was 330 mg in the starting material 
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% of total bindiq 
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Fig.2. Chromatofocusing of the partially purified IGF-binding 
protein on a Mono P column (FPLC system). The material ap- 
plied was that obtained from gel filtration (see section 3). The 
radioactivity peak corresponds to the elution peak of the IGF- 
BP complexes. The bars represent binding activity measured in 
aliquots of pooled fractions. 
(700 ml CSF), 8 mg in the material collected after 
gel filtration and 1 mg after step 3. In view of the 
minute quantities of material available, total pro- 
tein content was not determined after the final step. 
Binding activity in the starting material was 450 U. 
BP recovery after reverse-phase chromatography 
was estimated at 2% and 5% for the two purifica- 
tions, respectively. 
3.3. Characterization 
The purity of the protein obtained after the final 
chromatography was demonstrated by SDS-PAGE 
followed by ligand blotting and silver staining 
(fig.3). The BP isolated from the CSF of children 
migrated as a doublet with an estimated molecular 
mass of 34 kDa (non-reduced), which was the same 
as the doublet seen with ligand blotting in the star- 
ting material, The BP purified from adult CSF 
gave a single broad band which migrated slightly 
faster (- 32 kDa). 
In chromatofocusing, the purified BP eluted at 
pH 5.0. 
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Fig.3. Isolation by reverse-phase chromatography (C8 Aqua- 
phore, HPLC) of the IGF-binding protein. The peak cor- 
responds to material obtained after 2 successive runs. An ali- 
quot of the material was analysed by SDS-PAGE. 
The competitive-binding experiment done with 
the purified BP and 1251-IGF-II showed that IGF-II 
had a competitive potency 10 times that of IGF-I 
I I I I 1 I I 
0,l 0.2 0.4 0.8 1.6 3,l 6,3 12.5 
IGF (ng/ml) 
Fig.4. Competitive inhibition by IGF-I and IGF-II of the bind- 
ing of ‘251-labelled IGF-II to the IGF-binding protein purified 
from CSF. 
Table 1 
N-terminal amino acid sequences of the IGF-binding protein 
purified from cerebrospinal fluid 
Step number: 123456789101112131415 
CSF BP (children) 
CSF BP (adults) 
GH-dependent BP 69 P S P D E A,R P L 
AF BP 
,,I?$~$$$~;~ 
BRL-3A BP (rat) 63 P N P G S E L P L K A L V T G 
The two sequences determined for the BPS isolated from the 
CSF of children and adults were shown. (/) Used where no 
amino acid could be deduced. The CSF BP sequences have been 
aligned for purposes of comparison with the analogous regions 
of the GH-dependent BP [7], the amniotic fluid BP [13-161 and 
the BRL-3A BP [27] 
(fig.4). Scatchard analysis of binding data gave 
linear plots and the calculated affinity constants 
were 3 x 10” M-’ for IGF-II and 3 x lo9 M-’ for 
IGF-I . 
3.4. Amino acid sequence 
The N-terminal ends (first 15 residues) of the two 
BPS isolated, one from CSF of adults and the other 
from CSF of children, were sequenced (table 1). 
The sequence for the BP of children was obtained 
at a level of 50 pmol and, with the exception of step 
5, was easily identifiable. The sample from the 
adults was identifiable at low level (below 
20 pmol), and presented some amino acid con- 
taminants at steps 1, 2,6, 7, 8 and 14. Nonetheless, 
apart from residues 1 and 2, the sequence could be 
deduced without ambiguity. 
4. DISCUSSION 
In this study a purification scheme was establish- 
ed for isolating the IGF-binding protein form pre- 
dominant in CSF. Only small quantities of IGF 
were available and to this extent we selected ‘non- 
affinity’ approaches to purify the BP. The four- 
step procedure yielded a protein with an A4, of 
34 000 (non-reduced) and a pHi around 5. The elu- 
tion of the BP at 60% isopropanol in the reverse- 
phase step suggests that the BP is strongly hydro- 
phobic. 
This BP is distinguishable from the two ohter 
human BPS previously isolated in the following 
ways: (i) its molecular mass: under our electro- 
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phoretic conditions, the GH-dependent BP [6] ap- 
pears as a doublet of 42.5-38.5 kDa and the BP 
isolated from amniotic fluid (AF BP) [a,$] has an 
estimated Mr of about 39 QQQ [Z&4]; (ii) its pHt 
which is slightly less acidi@ than that of the AF BP 
around 4 [9]; (iii) as mentioned at the beginning of 
this article, it possesses no epitopes recognizable by 
the specific polyclonal antibodies to the other two 
BPS 141; (iv) its selective affinity for IGF-II which 
is ten times that for IGF-I, whereas purified 
preparations of the GH-dependent BP and AF BP 
have only slight differences in their affinities for 
IGF-I and IGF-II [6,25]. Nevertheless, the specific 
ability to bind IGFs, to the exclusion of all @@QF 
peptides, including insulin, implies some structural 
analogy between the various BPS. This has been 
confirmed for the BPS purified to date in man and 
in other species (review in [26]). It is also true for 
the CSF BP as shown by the amino acid sequence 
data. 
The sequences obtained for the two purified BP 
preparations were identical in children and adults, 
apart from two residues in positions 12 and 13. At 
present it is impossible to know whether the dif- 
ferences are due to sample origin or sequence 
variability. If different variants of CSF BP exist in 
adults and children, they may be in different pro- 
portions, and sample preparation could result in 
the isolation of one particular form. 
Comparison of the amino acid sequences deter- 
mined in our two BP preparations with the se- 
quences known for the other BPS shows analogous 
regions in sequences tarting from residue 69 of the 
GH-dependent BP (6 identical residues), from 
residue 61 of the AF BP (6 identical residues) and 
from residue 63 of a rat BP (5 identical residues) 
whose cDNA has recently been cloned from a 
BRL3A liver cell line [27]. This rat BP cor- 
responds to one we identified by ligand blotting as 
a 32 kDa species in rat liver culture media and 
serum where it is predominant in the fetus [5]. 
The CSF BP therefore appears to be related to 
the others. The question now arises whether or not 
the sequence really is at the N-terminal end of the 
protein, as the homology we have found with the 
other three BPS applies to zones beyond the 60th 
residue. The possibility of N-terminal end proteo- 
lysis during purification cannot be excluded. How- 
ever, the data from SDS-PAGE and the 
competitive-binding experiment strongly favour in- 
tqrity of the structure of the CSF BP and, more- 
over, an N-terminal sequence identical to the one 
determined in the CSF BP from children has been 
found in a BP purified from a human fetal lung 
fibroblast cell line (Ballard, J., personal com- 
munication). Studies under way to clone its cDNA 
should provide answers to this question. Nonethe- 
less, the data presented here are consistent with the 
conclusion that the BP isolated from CSF is a new 
species which is related to, but distinct from, the 
other human BPS purified to date. Its preponder- 
ance in CSF and its selective affinity for IGF-II 
suggest hat it plays some particular role in nervous 
tissue. 
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